« Back to Exclusive Articles

Making Sense of Fishy Findings: Reconciling the Omega-3 & Heart Disease Research

This content is restricted to members.

To view our premium content, sign up for a membership:


Register New Account

Choose your membership level

Choose Your Payment Method

‹ Back to Exclusive Articles


1. Nicholls S, Lincoff A, Garcia M, Bash D, Ballantyne C, Barter P et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk. JAMA. 2020;44195:1-13.
2. Oelrich B, Dewell A, Gardner C. Effect of fish oil supplementation on serum triglycerides, LDL cholesterol and LDL subfractions in hypertriglyceridemic adults. Nutrition, Metabolism and Cardiovascular Diseases. 2013;23(4):350-357.
3. Wei M, Jacobson T. Effects of Eicosapentaenoic Acid Versus Docosahexaenoic Acid on Serum Lipids: A Systematic Review and Meta-Analysis. Current Atherosclerosis Reports. 2011;13(6):474-483.
4. Hansen J, Grimsgaard S, Nilsen H, Nordøy A, Bønaa K. Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on fatty acid absorption, incorporation into serum phospholipids and postprandial triglyceridemia. Lipids. 1998;33(2):131-138.
5. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. The Lancet. 2007;369(9567):1090-1098.
6. Bhatt D, Steg P, Miller M, Brinton E, Jacobson T, Ketchum S et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. New England Journal of Medicine. 2019;380(1):11-22.
7. Budoff M, Muhlestein J, Bhatt D, Le Pa V, May H, Shaikh K et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results. Cardiovascular Research. 2020;41:3925–3932.
8. Endocrinologic and Metabolic Drugs Advisory Committee Briefing Document. Vascepa (icosapent ethyl), REDUCE-IT. November 14, 2019; 76-77, 112-114.

9. Ridker PM, Rifai N, MacFadyen J, et al. Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy. Circulation. 2022;146(5):372-379.
10. Watanabe T, Ando K, Daidoji H, Otaki Y, Sugawara S, Matsui M et al. A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins. Journal of Cardiology. 2017;70(6):537-544.
11. Cawood A, Ding R, Napper F, Young R, Williams J, Ward M et al. Eicosapentaenoic acid (EPA) from highly concentrated n−3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis. 2010;212(1):252-259.
12. GISSI Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. The Lancet. 1999;354(9177):447-455.
13. Thies F, Garry J, Yaqoob P, Rerkasem K, Williams J, Shearman C et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. The Lancet. 2003;361(9356):477-485.
14. Marchioli R, Barzi F, Bomba E. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction. time-course analysis of the results of the gruppo italiano per lo studio della sopravvivenza nell’infarcto miocardico (GISSI)-prevenzione. ACC Current Journal Review. 2002;11(6):15.
15. Kastelein J, Maki K, Susekov A, Ezhov M, Nordestgaard B, Machielse B et al. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. Journal of Clinical Lipidology. 2014;8(1):94-106.
16. Maki K, Orloff D, Nicholls S, Dunbar R, Roth E, Curcio D et al. A Highly Bioavailable Omega-3 Free Fatty Acid Formulation Improves the Cardiovascular Risk Profile in High-Risk, Statin-Treated Patients With Residual Hypertriglyceridemia (the ESPRIT Trial). Clinical Therapeutics. 2013;35(9):1400-1411.e3.
17. Price P, Nelson C, Clarke S. Omega-3 polyunsaturated fatty acid regulation of gene expression. Current Opinion in Lipidology. 2000;11(1):3-7.
18. Liu J, Green P, John Mann J, Rapoport S, Sublette M. Pathways of polyunsaturated fatty acid utilization: Implications for brain function in neuropsychiatric health and disease. Brain Research. 2015;1597:220-246.